Compare EVO & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVO | CGBD |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | Germany | United States |
| Employees | 4766 | 2500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.8M | 759.8M |
| IPO Year | N/A | N/A |
| Metric | EVO | CGBD |
|---|---|---|
| Price | $2.76 | $11.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $12.92 |
| AVG Volume (30 Days) | 106.1K | ★ 751.6K |
| Earning Date | 04-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 15.04% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.74 |
| Revenue Next Year | $0.21 | $1.80 |
| P/E Ratio | ★ N/A | $10.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $10.64 |
| 52 Week High | $4.80 | $15.15 |
| Indicator | EVO | CGBD |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 49.37 |
| Support Level | $2.32 | $10.64 |
| Resistance Level | $3.75 | $11.44 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 89.69 | 59.28 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.